{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.60","upperLimit":"5.92","value":"3.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Median PFS in months. Progressive Disease (PD): Increase of \\>= 25% from baseline. Estimated using the method of Kaplan-Meier.","dispersionType":"Full Range","groups":[{"description":"Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"AZD6244 (Selumetinib) Treatment"}],"paramType":"MEDIAN","populationDescription":"All participants who received study treatment","reportingStatus":"POSTED","timeFrame":"From registration to progression or death, assessed up to 2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}